[듀센형,DMD,SMT C1100]PCL 과 옥스퍼드 대학 약물 개발에 협력

영국의 생명 공학 회사 PLC는 영국의 옥스포드 대학에서 뒤 시엔 느 또는 베커 근이영양증에 대한 utrophin 기반 기술에 대한 권리를 인수했다. 치료로 이어질 수 있습니다  

PCL은 utrophin 단백질의 수준을 높이기 위해 설계 SMT C1100을 개발하고 테스트하는 MDA의지지를 받고있다,이 전략은 DMD 또는 BMD에 치료 될 수있다.

PCL은 최근 DMD와 소년의 SMT C1100을 테스트하기 위해 영국 규제 당국의 전진을 받았다.

옥스포드 교수 케이 데이비스는 DMD 또는 BMD에 대한 utrophin 기반의 치료법을 개발한 오랜 MDA 연구 교수입니다.

원문나갑니다.

MDA-supported biotechnology company Summit PLC has entered into a collaboration with the University of Oxford (United Kingdom) for continued development of utrophin modulators to treat Duchenne muscular dystrophy (DMD) and possibly Becker muscular dystrophy (BMD).

Laboratory studies have suggested that increasing levels of the utrophin protein in muscles may be therapeutic in DMD and/or BMD. Utrophin closely resembles the dystrophin protein, which is absent in DMD and reduced in BMD.

Summit, located in Abingdon, United Kingdom, made the announcement about its new strategic alliance in a Nov. 25, 2013, press release.

"We're very excited about this strategic alliance between Summit and Oxford," said Jane Larkindale, MDA's vice president of research. "We've been supporting the development of drugs that increase utrophin levels or activity for some time now, and the investment appears to have been a good choice. We hope a planned phase 1b study of a utrophin modulator in children with Duchenne muscular dystrophy shows encouraging results."

Summit CEO Glyn Edwards said, "This strategic alliance secures Summit's position as the world leader in the development of utrophin-based therapies for the treatment of DMD and enhances our opportunity of generating effective treatments for this devastating disease."

In late 2011, Summit received a $750,000 grant from MDA for development and testing of SMT C1100, its lead utrophin modulator. Earlier this month, Summit received approval from regulatory authorities in the UK to test SMT C1100 in boys with DMD.

Summit to acquire rights to Oxford drugs, technology

As part of this new alliance, Summit will acquire exclusive commercial rights to a pipeline of new, early-stage utrophin modulators and to core biological screening technology developed at Oxford. Summit will also have an exclusive option over intellectual property generated from a research collaboration with laboratories at Oxford.

The new utrophin drugs and screening technology have been developed at the University of Oxford by research teams led by MDA grantee Kay Davies, who has received MDA support for utrophin development for several years. Most recently, Davies received a 2012 grant and a 2013 grant to screen for drugs that can increase levels or activity of the utrophin protein.

출처:http://quest.mda.org/news/dmd-bmd-summit-and-university-oxford-collaborate-drug-development